Warning on biosimilar burden

A higher than usual degree of pharmacovigilance is required when patients are switched to new biosimilar medications, say Australian experts Writing in the latest Australian Prescriber two pharmacy academics have stressed that, in comparison with traditional small-molecule drugs, biosimilars have unique safety considerations. Owing to the diversity in their structural complexity and indications, safety will need

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Pharmacy retail ratings released
Next Clinical tips: quit smoking